Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Speciality MedicinesBOM:544738 -6.76%21 ROA % is 24.21% as of Mar. 2026, which is 26% above its 10-year median of 19.28. GuruFocus rates BOM:544738 with a GF Score™ of 21/100. The stock has 3 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Speciality Medicines ranks better than 88% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Speciality Medicines's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹163.7 Mil.
Speciality Medicines's average Total Assets over the quarter that ended in Mar. 2026 was ₹676.0 Mil. Therefore, Speciality Medicines's annualized ROA % for the quarter that ended in Mar. 2026 was 24.21%.
The historical rank and industry rank for Speciality Medicines's ROA % or its related term are showing as below:
BOM:544738'
s ROA % Range Over the Past 10 Years
Min: 12.1 Med: 19.28 Max: 25.61
Current: 12.1
During the past 5 years, Speciality Medicines's highest ROA % was 25.61%. The lowest was 12.10%. And the median was 19.28%.
BOM:544738's ROA % is ranked better than 88% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 2.565
vs BOM:544738: 12.10
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Mar. 2026) net income data. The Revenue data used here is two times the semi-annual (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Speciality Medicines ROA % Chart
Speciality Medicines Annual Data
Trend
Mar22
Mar23
Mar24
Mar25
Mar26
ROA %
25.61
17.82
16.32
22.97
19.28
Speciality Medicines Semi-Annual Data
Mar22
Mar23
Mar24
Mar25
Mar26
ROA %
0.00
0.00
0.00
17.13
24.21
BOM:544738 vs ZTS: ROA % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Speciality Medicines's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Speciality Medicines ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Speciality Medicines's ROA % distribution charts can be found below:
* The bar in red indicates where Speciality Medicines's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Speciality Medicines (BOM:544738) has a ROA % of 24.21% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Speciality Medicines and its competitors. This is 26% above median its historical median of 19.28. Over the past decade, Speciality Medicines' ROA % has ranged from 12.10 to 25.61. According to the industry distribution chart, Speciality Medicines ranks #121 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 12%.
Is Speciality Medicines' ROA % too high?
Speciality Medicines' current ROA % of 24.21% is 26% above median its 10-year median of 19.28. Over the past 10 years, this metric has ranged from a low of 12.10 to a high of 25.61. The Drug Manufacturers industry median ROA % is 2.57. Speciality Medicines' value of 24.21% is 843.9% above this industry median. Based on the distribution chart, Speciality Medicines ranks #121 out of 1008 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Speciality Medicines has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Speciality Medicines' ROA % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Speciality Medicines ranks #121 out of 1008 companies for ROA %. This places Speciality Medicines in the top 12% of its industry — outperforming the majority of peers. The industry median ROA % is 2.57. Speciality Medicines' value of 24.21% is 843.9% above this benchmark. Historically, Speciality Medicines' own ROA % has ranged from 12.10 to 25.61 over the past decade. While the company's 10-year median is 19.28 vs. the industry median of 2.57, Speciality Medicines has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.57, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Speciality Medicines's current ROA % of 24.21% is 843.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Speciality Medicines and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Speciality Medicines's current ROA % is 24.21%, which is 26% above median its own 10-year median of 19.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Speciality Medicines stock overvalued right now?
Speciality Medicines (BOM:544738) has a current ROA % of 24.21%. The current ROA % is 24.21%, which is 26% above median its 10-year median of 19.28 and 843.9% above the Drug Manufacturers industry median of 2.57. Speciality Medicines' overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Speciality Medicines (BOM:544738), the current ROA % is 24.21% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Speciality Medicines Ltd is engaged in the marketing and distribution of finished formulations of specialty pharmaceutical products, comprising oral and injectable medications used in the treatment of complex and chronic medical conditions in therapeutic areas like oncology, immunology, neurology and rare diseases. Its product range includes various dosage forms such as tablets, capsules, syrups, injections, infusions, inhalers, sprays, and topical formulations. The company operates through two business models: (a) Manufacturing, through contract manufacturing basis, and (b) Marketing and distribution of specialty pharmaceutical products sourced from manufacturers. The majority of the company's revenue is derived from the sale of its projects, mainly through exports to other countries.
21GF Score
Get the complete analysis for BOM:544738
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544738 has been successfully added to your 
